Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Bloomios's EV-to-EBIT or its related term are showing as below:
BLMS's EV-to-EBIT is not ranked *
in the Drug Manufacturers industry.
Industry Median: 15.855 * Ranked among companies with meaningful EV-to-EBIT only.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Bloomios's Enterprise Value for the quarter that ended in Sep. 2023 was $33.28 Mil.
Bloomios's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-36.81 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bloomios EV-to-EBIT Related Terms
Bloomios EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Bloomios's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bloomios's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bloomios EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bloomios's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Bloomios's EV-to-EBIT falls into.
Bloomios's current Enterprise Value is $33.09 Mil.
Bloomios's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-36.81 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bloomios (BLMS) has a EV-to-EBIT of -0.90 as of Aug. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bloomios and its competitors.
Is Bloomios' EV-to-EBIT too high?
Bloomios' current EV-to-EBIT is -0.90.
How does Bloomios' EV-to-EBIT compare to MJNE and ACORQ?
Bloomios' EV-to-EBIT of -0.90 can be compared against companies in the Drug Manufacturers industry. The industry median EV-to-EBIT is 15.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.86, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bloomios and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bloomios's current EV-to-EBIT is -0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bloomios stock overvalued right now?
Bloomios (BLMS) has a current EV-to-EBIT of -0.90. The current EV-to-EBIT is -0.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Bloomios (BLMS), the current EV-to-EBIT is -0.90 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bloomios Inc manufactures, markets, and distributes U.S. hemp-derived supplements and cosmetic products through wholesale distribution channels in the United States of America. It offers its private-label and white-label customers large collections of customizable hemp products that include over 80 products across 7 categories in addition to custom formulation and manufacturing services. Its product categories include edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages, and pet treats.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLMS has been successfully added to your 
